Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc.

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, September 19, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Central nervous system, Drug development, Therapy, Senior, Hologic, ACAD, Corporate communication, Wall Street, Minerva Surgical, Inc. v. Hologic, Inc., Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., Saint Petersburg State University of Economics and Finance, Patient, Vital, Incorporated, Growth, Management, Economics, Halozyme, Boston College

(Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications.

Key Points: 
  • (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications.
  • Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee.
  • “Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry,” said Mark Schneyer, Executive Vice President, Chief Financial Officer.
  • Prior to Halozyme, Al oversaw investor relations and business development at Vital Therapies, Inc., and investor relations at Hologic, Inc. and Gen-probe Incorporated.

MKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia’s 2023 Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Professional Services, Finance, Annual Meetings of the International Monetary Fund and the World Bank Group, Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., Annual general meeting, Capital, MKT, Policy, Compensated emancipation, Security (finance), Management, Aurinia

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today commented on the outcome of the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023.

Key Points: 
  • MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today commented on the outcome of the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023.
  • At the Annual Meeting, Chairman George Milne and Compensation Committee Chair Joseph Hagan received less than majority support from shareholders and have subsequently submitted their resignations to the Board of Directors (the “Board”), pursuant to the Company’s Majority Voting Policy.
  • Additionally, the Company’s non-binding advisory vote on executive compensation did not receive majority support and the proposed amendment to the equity incentive plan was not approved.
  • “We appreciate that our fellow shareholders considered MKT Capital’s views and ultimately sent a clear message to Aurinia at this year’s Annual Meeting.

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Retrieved on: 
Tuesday, May 2, 2023
Infection, Flare, Heart failure, Hospital, TB, Kidney, Medicine, History, Marketing, Sepsis, Boehringer Ingelheim, Breakthrough therapy, Patient, Tuberculosis, Risk, Immune system, Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., GPP, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mental health, Food, Safety, Birth control, Pharmaceutical industry, Dermatology

GPP is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread eruptions of painful, sterile pustules across the body.

Key Points: 
  • GPP is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread eruptions of painful, sterile pustules across the body.
  • Flares greatly affect a person's quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
  • "The FDA's action reinforces the potential of spesolimab and represents a critical step in bringing this treatment to patients who need it most.
  • Spesolimab is marketed as SPEVIGO (spesolimab-sbzo) injection, for intravenous use by Boehringer Ingelheim
    Pharmaceuticals, Inc. (BIPI) and is indicated for the treatment of GPP flares in adults.

FDA Awards $1.3 Million Grant to Biologics & Biosimilars Collective Intelligence Consortium

Retrieved on: 
Monday, October 3, 2022
Pharmacist, Association, Pharmacy, Population Health Management, Physician, Review, Research, Economics, Optum, Amgen, FDA, Merck, Safety, Efficiency, Patient, AMCP, Nursing, Biopharmaceutical, Organization, RWE, Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., RWD, AbbVie, HealthPartners, Generic drug, Pharmaceutical industry, IQVIA, Novartis, Pfizer

ALEXANDRIA, Va., Oct. 3, 2022 /PRNewswire/ -- The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announcedtodaythatithasreceivedamajorgrantfromtheFood& Drug Administration (FDA) in support of biosimilars research.

Key Points: 
  • ALEXANDRIA, Va., Oct. 3, 2022 /PRNewswire/ -- The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announcedtodaythatithasreceivedamajorgrantfromtheFood& Drug Administration (FDA) in support of biosimilars research.
  • The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.
  • Thestudyentitled"ImprovingtheEfficiencyofRegulatoryDecisions forBiosimilarsand Interchangeable Biosimilars by Leveraging Real-World Data to Produce Real-World Evidence"reflects BBCIC's longstanding commitment to evaluating the safety and effectiveness of biologics, including biosimilars, through the generation of reliable, real- world data (RWD) and evidence (RWE).
  • "The challenges in using real-world data and the relevance of real-world evidence for regulatorydecision-makingaboutbiosimilarsis amajorobstacle intheindustry,"saidCate Lockhart, Executive Director of the BBCIC.

Magnus Adds Three Key Hires to Executive Team

Retrieved on: 
Thursday, March 10, 2022
Mental Health, Health, FDA, Medical Devices, Hospitals, Other Health, Biotechnology, Industry, Medicine, Suicide, Business incubator, Spectranet, Marketing, Compliance, Magnus, III, FDA, Forest Laboratories, SAINT, RCT, Depression, Pain, Multimedia, Psychiatry, Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., The American Journal of Psychiatry, Brain, American Journal, Record, St. Jude Medical, Neuronetics, Technology, Timothy, Lists of diseases, CEO, Engineering, Federal, Musicam sacram, Peripheral artery disease, Management, Pharmaceutical industry, Medical device, LLC

Magnus Medical, Inc. , a medical device company developing a novel, rapid-acting brain stimulation technology designed to treat adults suffering from neuropsychiatric disorders, today announced the appointment of three executives to key positions on the leadership team.

Key Points: 
  • Magnus Medical, Inc. , a medical device company developing a novel, rapid-acting brain stimulation technology designed to treat adults suffering from neuropsychiatric disorders, today announced the appointment of three executives to key positions on the leadership team.
  • We are excited to expand our team by adding three very impressive executives, said Brett Wingeier, Ph.D., co-founder and CEO of Magnus Medical.
  • Erica, Tammy, and Timothy bring deep industry expertise and highly successful track records in development, validation, and commercialization of groundbreaking medical devices.
  • Timothy Hale joins Magnus with over 20 years of medical device and pharmaceutical industry experience in launching and commercializing disruptive technologies and indications.